Picture the patient you will absolutely meet: someone whose depression has survived two, three, four antidepressants, who has stopped believing anything will work, and who walks into a clinic for their first ketamine session and — sometimes within hours — feels the fog lift for the first time in years. It is one of the most genuinely hopeful moments in modern psychiatry. And it is also the moment where a whole generation of clinicians is quietly getting the safety part wrong, because the thing that makes ketamine miraculous and the thing that makes it dangerous are the same thing: the dose, and how often you give it. This is the post that teaches you to hold both truths at once.
Ketamine is having its era. Once a battlefield and operating-room anesthetic, it re-entered psychiatry after researchers first demonstrated its rapid antidepressant effects around the year 2000, and the evidence base has since become, in the words of Weill Cornell’s Benjamin Brody, MD, “an absolute mountain of literature.” In January 2025 the FDA approved Spravato — intranasal esketamine — as the first and only monotherapy for treatment-resistant depression, a milestone that pulled ketamine even further into the mainstream. For a PMHNP student, that means this is no longer an exotic subspecialty topic. It is coming to your clinic, your board exam, and your patients. The question is whether you’ll understand it well enough to use it the way it’s meant to be used.
Why the dosing interval is the whole story
Here is the single most important concept in this entire subject, and it is one that too many prescribers skip right past. At the 2026 American Society of Clinical Psychopharmacology meeting, Dr. Brody framed it with unusual clarity: “At low doses, with appropriate intervals between administration, ketamine probably has neurotrophic effects. However, if it’s dosed at higher doses and without appropriate intervals between dosing — or if it’s dosed too frequently — at some point it becomes neurotoxic.”
Read that twice. The same molecule can grow the brain or injure it. The variable isn’t good ketamine versus bad ketamine — it’s dose and frequency. At the low doses and spaced schedules used in supervised depression treatment, ketamine appears to promote synaptogenesis, the rapid formation of new synaptic connections that is thought to underlie its antidepressant punch. Push the dose higher, stack the sessions too close together, and you cross an invisible threshold where the neurotrophic story flips into a neurotoxic one. A 2025 review in The American Journal of Psychiatry led by Samuel Wilkinson’s group — with the pointed title “Ketamine for Depression, but at What Cost?” — pulled together the preclinical and human evidence for exactly this dose- and frequency-dependent neurotoxicity, and made the case that we still don’t know precisely where that line sits. That uncertainty is not a reason to panic. It’s a reason to respect the schedule.
For you as a future prescriber, this reframes everything. When you see a ketamine or esketamine protocol — twice weekly during induction, then tapering to once weekly and eventually every other week in maintenance — that spacing is not bureaucratic caution. It is the safety mechanism. The interval is the guardrail. A patient who talks you into “just squeezing in an extra session because it’s wearing off” is asking you to trade a known safety margin for a short-term feeling, and knowing why you’d say no is the mark of a clinician who actually understands the drug.

The acute monitoring you cannot skip
The second pillar of ketamine safety is what happens in the room, in real time, during and right after a dose. And here’s a reassuring fact for anyone feeling overwhelmed by how new all this seems: the core safeguards are not new at all. The American Psychiatric Association’s 2017 consensus statement on ketamine in mood disorders, published in JAMA Psychiatry by Sanacora, Frye, McDonald and colleagues, already spelled them out, and Dr. Brody points out that those recommendations “remain highly relevant today.”
What do they require? Two things above all. First, monitor vital signs — ketamine reliably bumps blood pressure and heart rate, and you need to catch a hypertensive spike before it becomes a problem. Second, keep eyes on the patient with in-person observation for dissociation, watching for the moment when a dissociative experience shifts from the transient, expected, even therapeutic altered state into something frightening or clinically problematic. Dissociation and sedation are the signature acute effects, and they are usually short-lived, but “usually” is not “always,” and the whole point of supervision is to be present for the exception.
This is exactly why the Spravato REMS — Risk Evaluation and Mitigation Strategy — program is built the way it is, and why boards love to test its mechanics. Esketamine cannot be taken home. It is self-administered by the patient but only under supervision in a certified healthcare setting. The patient must be monitored for at least two hours after the dose. And they cannot drive until the next day after a full night’s sleep. If you can recite that quartet — certified setting, in-clinic administration, two-hour monitoring, no driving until the next day — you understand both an exam favorite and the practical reason a ketamine clinic runs the way it does. None of it is arbitrary. Every rule maps back to sedation, dissociation, blood pressure, and the potential for misuse.
The bladder is the warning nobody expects
Now for the complication that catches even seasoned clinicians off guard, because it lives so far from where psychiatry usually looks: the urinary tract. Ketamine-induced uropathy, sometimes called ketamine cystitis, is a real and increasingly recognized harm. A 2025 review in the journal Addiction and a companion analysis in The Journal of Clinical Psychiatry describe a syndrome of urinary frequency, urgency, painful urination, blood in the urine, and lower abdominal pain — driven by bladder inflammation, damage to the protective urothelial lining, and direct toxicity from ketamine and its metabolites concentrated in the urine. In heavy recreational users, roughly one in four report lower urinary tract symptoms, and in severe chronic cases the bladder can become scarred and shrunken.
Here is the nuance that keeps you honest, and it’s the same nuance running through this whole topic: the severe cases are overwhelmingly tied to frequent, high-dose recreational use, not to supervised, low-dose, appropriately spaced therapeutic dosing. The same is true of the cognitive effects — memory impairment shows up in frequent recreational ketamine users but has largely not borne out in controlled trials of therapeutic use. So this isn’t a reason to fear the treatment. It is a reason to ask about urinary symptoms at follow-up, to know that they can occur, and — critically — to recognize them when a patient who’s been using ketamine outside of clinical channels shows up in your office with bladder complaints and no obvious explanation. The management is multidisciplinary: primary care for early recognition, urology for the bladder itself, and addiction medicine when a use disorder is driving it. A PMHNP who knows to connect “young patient, recurrent cystitis, no infection” to ketamine is a PMHNP who catches what others miss.

Where the evidence gets thin
One more layer of honesty, because it’s the kind of thing that separates a careful clinician from an enthusiastic one. The mountain of ketamine evidence is tall in exactly one place — treatment-resistant depression and acute suicidality in mood disorders — and much thinner everywhere else. As Dr. Brody put it, “We have much less data on ketamine use outside of treatment-resistant depression.” The special populations where clinicians most want answers — patients with bipolar disorder, co-occurring borderline personality disorder, older adults, and the medically complex or terminally ill — are precisely the ones where the research is sparsest and the risk-benefit math shifts.
The independent-minded folks at The Carlat Psychiatry Report — Dr. Daniel Carlat’s team, whose whole brand is unbiased, industry-free analysis — have been steady voices reminding clinicians that “rapid” and “impressive” are not the same as “well understood over the long haul,” even while covering the practical mechanics of implementing subanesthetic IV ketamine safely on inpatient units. That posture — enthusiastic about the tool, humble about the gaps — is the one to model. When a drug is genuinely helping desperate patients, the temptation is to wave away the unknowns. The better move, and the one your future patients deserve, is to keep offering the treatment where the evidence supports it while staying honest that the map still has blank spaces.
What this means for you
Ketamine is a near-perfect teaching case for how to think like a PMHNP, because it refuses to be reduced to a slogan. It is not “miracle drug” and it is not “dangerous street anesthetic.” It is a genuinely powerful, genuinely limited intervention whose safety lives almost entirely in how it’s used rather than whether it’s used. Anchor to a few durable ideas and you’ll carry them into the exam room and the clinic alike: the dosing interval is a safety feature, not a scheduling detail; acute monitoring means vital signs plus watchful observation for dissociation, per the APA’s long-standing consensus; the Spravato REMS structure — certified setting, two-hour monitoring, no same-day driving — exists for concrete pharmacologic reasons; and the bladder and the brain both have thresholds that recreational misuse blows past and supervised care is designed to protect.
Hold those together and you’re doing the exact thing your boards are built to measure and your patients will quietly rely on: weighing a real benefit against a real risk, in real time, without collapsing into either hype or fear. The patient in our opening scene — the one who felt the fog lift — deserves a clinician who can protect that moment and make it last, not just deliver it once. That clinician understands that with ketamine, the schedule is the medicine’s conscience.
You’re studying this because you want to be that clinician — the one who can explain to a patient why the interval matters, catch the bladder symptom nobody connected, and recite the REMS rules without blinking. Keep building that instinct, one high-yield mechanism at a time. Ready to turn the trickiest, most testable topics in psychopharmacology into points on exam day and confidence in the clinic? Come study with us at PMHNP Review, where we make the “why” behind every guardrail stick.
